Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Thrive prospers with $257m round
Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.
Sema4 sequences $121m series C
Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.
Praxis Precision works out $110m series C1
Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.
Coursera enrols in $130m series F round
Seek Group returned for a series F round that boosted the Stanford faculty-founded adult education provider's valuation to $2.5bn.
CureVac cuts $176m equity deal with GSK
GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.
Harbour BioMed hoards series C funding
The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.
Vor leaps into $110m series B
Columbia University’s Vor Biopharma has collected more capital from shareholders including Osage University Partners, Johnson & Johnson and PureTech Health.
Annexon adds $100m
The round pushed the overall funding for Stanford's autoimmune and neurodegenerative disorder drug developer past $250m.

Other News

Goldfinch Bio sparks $100m series B
Advancing research from institutions including Harvard, kidney disease-focused Goldfinch Bio now has its sights on clinical trials.
Freeline captures $120m series C
Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.
Pionyr maps out $1.47bn Gilead deal
Gilead Sciences will invest $275m for a 49.9% stake in the UofT and UCSF-linked company as part of a $1.47bn deal to potentially purchase Pionyr outright.
Orca Bio organises $192m series D
Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.
Volkswagen to drive $200m to QuantumScape
The carmaker has followed up a $100m investment two years ago with a pledge to provide up to $200m for the Stanford-originated solid-state battery developer.
C4 Therapeutics seals $170m round
The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg